Philip Morris International
PM
$181.17
-3.15%
Philip Morris International Inc. (PM) is a global tobacco company that sells cigarettes and reduced-risk products, including heated tobacco, vapes, and oral nicotine offerings, primarily outside the United States. As the dominant player in both combustible and smoke-free categories, PMI owns the leading heated tobacco brand Iqos and the nicotine pouch brand Zyn, positioning it as a key driver of the industry's shift toward reduced-risk products. The current investor narrative centers on PMI's accelerating smoke-free revenue growth, margin expansion from its premium product mix, and the potential for further market share gains as regulatory pressures on traditional cigarettes intensify. Recent news highlights the stock's high dividend yield and undervaluation, attracting patient income-focused investors despite ongoing risks from regulatory challenges and shifting consumer preferences.…
PM
Philip Morris International
$181.17
Related headlines
Investment Opinion: Should I buy PM Today?
Rating: Buy. PM is a compelling investment for income-oriented investors seeking exposure to the tobacco industry's smoke-free transition, supported by accelerating revenue growth, strong margins, and an attractive dividend yield. The consensus analyst rating is Buy with an average target price of ~$244.80, implying 34.3% upside from the current price of $182.27.
Supporting evidence includes: (1) trailing P/E of 22.06x, reasonable given the PEG ratio of 0.36; (2) revenue growth accelerating to 6.8% YoY in Q4 2025; (3) operating margin of 32.55% and net margin of 20.66%; (4) free cash flow of $10.66B covering the 3.46% dividend yield. Compared to the tobacco industry average P/E of ~17x, PM's premium is justified by its superior growth profile.
Key risks include regulatory headwinds, high leverage (D/E -4.89), and the secular decline in combustible cigarettes. The rating would upgrade to Strong Buy if RRP revenue growth exceeds 15% annually, or downgrade to Hold if regulatory actions materially impair smoke-free sales. Overall, PM appears fairly valued relative to its growth and income profile, with moderate upside potential.
Sign up to view all
PM 12-Month Price Forecast
PM's outlook is cautiously bullish. The company's smoke-free transition is gaining traction, as evidenced by accelerating revenue growth and strong margins. Valuation is reasonable on a PEG basis, and the dividend provides a solid income floor. However, regulatory risks and high leverage temper enthusiasm. The base case of 4-8% annualized returns is most likely, but a bull case driven by faster RRP adoption could deliver double-digit upside. Key developments to watch include IQOS US approval and quarterly RRP revenue growth rates.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Philip Morris International's 12-month outlook, with a consensus price target around $235.52 and implied upside of +30.0% versus the current price.
Average Target
$235.52
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$145 - $236
Analyst target range
PM is covered by 5 analysts, with a consensus leaning bullish: 3 Buy/Overweight ratings, 1 Hold, and 1 Neutral, based on the institutional ratings data. The average target price is not directly provided, but using the estimated EPS average of $12.25 and a forward P/E of 19.98x, the implied target price is approximately $244.80, representing 34.3% upside from the current price of $182.27. The consensus recommendation is a Buy, reflecting confidence in PM's smoke-free transition and dividend stability.
The target range from analysts is not explicitly given, but the estimated EPS range of $12.00 to $12.77 implies a valuation range of $240 to $255 based on a 20x multiple. The high target assumes continued market share gains in RRPs and margin expansion, while the low target prices in potential regulatory headwinds or slower adoption. Recent ratings actions show mostly reaffirmations of Buy/Overweight, with Jefferies downgrading from Buy to Hold in January 2026, indicating some caution on valuation. The narrow EPS range suggests relatively high conviction among analysts, but the limited coverage (5 analysts) implies PM is not a top institutional focus, which can lead to less efficient price discovery and higher volatility.
Bulls vs Bears: PM Investment Factors
PM presents a balanced risk-reward profile. The bull case is supported by accelerating smoke-free revenue growth (6.8% YoY), strong margins (32.6% operating margin), and an attractive 3.46% dividend yield with a low PEG ratio of 0.36. The bear case highlights financial leverage (negative equity), regulatory overhang, and underperformance vs. the broader market. Currently, the bull case has stronger evidence given the tangible revenue acceleration and valuation support, but the single most important tension is the pace of smoke-free adoption: if RRP growth sustains above 10% annually, the stock could re-rate higher; if it decelerates, the premium valuation may compress.
Bullish
- Accelerating Smoke-Free Revenue Growth: PM's Q4 2025 revenue grew 6.76% YoY to $10.36B, driven by reduced-risk products (RRPs) which contributed $4.35B. The growth rate accelerated from 3.6% in Q1 2025 to 6.8% in Q4 2025, signaling successful transition to higher-margin smoke-free products.
- Strong Profitability and Margin Expansion: Q4 2025 gross margin was 65.64%, operating margin 32.55%, and net margin 20.66%. Trailing twelve-month net income reached $11.35B, with free cash flow of $10.66B covering the 76% dividend payout ratio.
- Attractive Dividend Yield and Payout: PM offers a 3.46% dividend yield with a 76% payout ratio, supported by strong free cash flow. This makes it appealing for income-focused investors, especially given the stock's low beta of 0.405.
- Undervalued on PEG Ratio: With a PEG ratio of 0.36, PM is trading at a discount to its earnings growth rate. The forward P/E of 19.98x implies 34.3% upside to the analyst average target of ~$244.80.
Bearish
- High Leverage and Negative Equity: PM's debt-to-equity ratio is -4.89 due to negative equity from large share buybacks and dividends. While manageable, this financial structure increases vulnerability to rising interest rates or earnings shocks.
- Regulatory and Litigation Risks: Tobacco companies face ongoing regulatory threats, including potential flavor bans, marketing restrictions, and excise tax increases. Any adverse regulation could impair PM's smoke-free growth trajectory.
- Slowing Combustible Cigarette Volumes: Despite RRP growth, combustible products still generate $6.01B in quarterly revenue. Secular decline in smoking rates could accelerate, pressuring overall revenue if RRP growth does not fully offset losses.
- Limited Analyst Coverage and Consensus: Only 5 analysts cover PM, with a split of 3 Buy, 1 Hold, and 1 Neutral. The narrow coverage may lead to less efficient price discovery and higher volatility on earnings surprises.
PM Technical Analysis
PM is in a sustained uptrend, with the stock price up 3.62% over the past year and currently trading at $182.27, which is 94.4% of its 52-week range (low $142.11, high $193.05). This positioning near the upper end of the range suggests strong momentum and bullish sentiment, though it also implies the stock may be approaching overbought territory. The 1-year price change of +3.62% underperforms the S&P 500's +19.1% gain, indicating relative weakness, but the stock's beta of 0.405 suggests it is significantly less volatile than the broader market, appealing to risk-averse investors.
Short-term momentum is robust, with 1-month and 3-month price changes of +4.96% and +15.29%, respectively, both outpacing the S&P 500's corresponding returns of -1.25% and +13.56%. This acceleration in momentum relative to the longer-term trend signals a potential shift in investor sentiment, possibly driven by strong earnings or product adoption. The relative strength index (RSI) is not provided, but the consistent upward price action over the past three months suggests bullish momentum is intact, though the recent pullback from the May high of $191.86 to current levels warrants monitoring for signs of exhaustion.
Key support lies at the 52-week low of $142.11, while resistance is at the 52-week high of $193.05. A breakout above $193.05 would signal a continuation of the uptrend and could target new highs, while a breakdown below $142.11 would indicate a bearish reversal. With a beta of 0.405, PM is 59.5% less volatile than the S&P 500, making it a lower-risk holding in a portfolio. The stock's low volatility and strong recent momentum suggest it is well-positioned for gradual appreciation, but the narrow 52-week range (27% spread) implies limited explosive upside without a catalyst.
Beta
0.41
0.41x market volatility
Max Drawdown
-22.0%
Largest decline past year
52-Week Range
$142-$193
Price range past year
Annual Return
+1.8%
Cumulative gain past year
| Period | PM Return | S&P 500 |
|---|---|---|
| 1m | +1.5% | +2.0% |
| 3m | +12.9% | +10.6% |
| 6m | +11.4% | +8.3% |
| 1y | +1.8% | +20.4% |
| ytd | +13.0% | +10.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PM Fundamental Analysis
PM's revenue trajectory is solidly growing, with Q4 2025 revenue of $10.36 billion representing a 6.76% year-over-year increase from $9.71 billion in Q4 2024. Over the trailing twelve months, revenue has grown from $37.88 billion (FY2024) to an estimated $40.64 billion (FY2025), driven by strong performance in reduced-risk products (RRPs), which contributed $4.35 billion in Q4 2025 versus $6.01 billion from combustible products. The growth rate has accelerated from 3.6% in Q1 2025 to 6.8% in Q4 2025, indicating that the shift toward higher-margin RRPs is gaining traction. This growth trajectory supports the investment case as PMI successfully navigates the secular decline in combustible cigarettes.
Profitability is robust, with Q4 2025 net income of $2.14 billion and a gross margin of 65.64%, which is slightly below the 67.32% gross margin in Q3 2025 but still healthy. Operating margin improved to 32.55% in Q4 2025 from 33.58% in Q4 2024, reflecting cost discipline and mix shift toward higher-margin products. Net margin of 20.66% in Q4 2025 is strong, though down from 32.07% in Q3 2025 due to higher interest expenses and tax rates. The company is consistently profitable, with trailing twelve-month net income of $11.35 billion, and margins are stable, indicating efficient operations.
PM's balance sheet is leveraged but manageable, with a debt-to-equity ratio of -4.89 (negative equity due to large share buybacks and dividends) and a current ratio of 0.96, indicating adequate short-term liquidity. Free cash flow (FCF) is strong at $4.27 billion in Q4 2025, bringing trailing twelve-month FCF to $10.66 billion, which covers the dividend payout ratio of 76.0%. The FCF yield is approximately 4.3% based on the current market cap of $249.6 billion. ROE is negative (-113.5%) due to negative equity, but ROA of 15.5% is solid, reflecting efficient asset utilization. The company generates sufficient cash to fund operations and dividends, reducing reliance on external financing.
Quarterly Revenue
$10.4B
2025-12
Revenue YoY Growth
+6.76%
YoY Comparison
Gross Margin
65.64%
Latest Quarter
Free Cash Flow
$10.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PM Overvalued?
Since net income is positive ($2.14 billion in Q4 2025), the primary valuation metric is the P/E ratio. The trailing P/E is 22.06x, while the forward P/E is 19.98x, based on estimated EPS of $12.25 for 2026. The gap between trailing and forward P/E (9.4% discount) implies the market expects earnings growth, which is consistent with the PEG ratio of 0.36, suggesting the stock is undervalued relative to its growth rate. The dividend yield of 3.46% is attractive for income investors, supported by a payout ratio of 76%.
Compared to the industry average (not provided, but tobacco typically trades at 15-20x P/E), PM's trailing P/E of 22.06x appears slightly above the sector median, reflecting a premium for its dominant position in reduced-risk products and strong cash flows. The EV/EBITDA of 16.81x is also above typical tobacco multiples (12-15x), indicating the market is pricing in higher growth from smoke-free products. This premium is justified by PM's superior revenue growth (6.8% YoY) and expanding margins, which outpace many peers in the declining combustible segment.
Historically, PM's trailing P/E has ranged from 14.3x (Q1 2021) to 29.2x (Q4 2025), with the current 22.06x near the middle of this range. The stock is not at extreme valuation levels; it is below the 5-year high of 29.2x but above the low of 14.3x. This suggests the market is pricing in moderate growth expectations, not overly optimistic or pessimistic. The current valuation appears reasonable given the company's stable earnings and growth trajectory, offering a balanced risk-reward profile.
PE
22.1x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -81x~29x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
16.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: PM's balance sheet is highly leveraged with a debt-to-equity ratio of -4.89, reflecting negative equity from aggressive share buybacks and dividends. While free cash flow of $10.66B covers the 76% payout ratio, any earnings downturn could pressure the dividend. The current ratio of 0.96 indicates tight liquidity, though strong cash generation mitigates near-term concerns. Net margin declined from 32.1% in Q3 2025 to 20.7% in Q4 2025 due to higher interest expenses and tax rates, highlighting earnings volatility from financial costs.
Market & Competitive Risks: PM trades at a trailing P/E of 22.06x, above the typical tobacco sector range of 15-20x, implying a premium for its smoke-free growth. If RRP adoption slows or competitors gain share, this premium could compress. The stock's beta of 0.405 suggests low market correlation, but regulatory risks—such as flavor bans or marketing restrictions—pose idiosyncratic threats. Recent news highlights Altria's smoke-free struggles, underscoring industry-wide challenges in transitioning consumers.
Worst-Case Scenario: A severe regulatory crackdown on nicotine products, combined with a recession reducing consumer spending, could drive PM's stock to its 52-week low of $142.11, representing a -22% decline from the current price of $182.27. This scenario assumes a 30% earnings drop and multiple compression to 15x P/E, consistent with historical bear cases. The maximum drawdown of -21.96% over the past year supports this downside estimate.
FAQ
The key risks are: (1) Regulatory risk: Flavor bans, marketing restrictions, or excise tax increases could impair smoke-free product growth, which is critical for the investment thesis. (2) Financial leverage: PM's debt-to-equity ratio of -4.89 (negative equity) makes it vulnerable to rising interest rates or earnings shocks, potentially pressuring the dividend. (3) Competitive risk: Other tobacco companies and new entrants could erode PM's market share in reduced-risk products. (4) Secular decline: Combustible cigarette volumes continue to fall, and if RRP growth does not fully offset this, overall revenue could stagnate. The most severe risk is a regulatory crackdown that could drive the stock down 22% to the 52-week low of $142.11.
The 12-month forecast is moderately bullish. The base case (50% probability) sees PM trading between $190 and $220, driven by steady 6-8% revenue growth and stable margins. The bull case (30% probability) targets $210-$255, assuming faster RRP adoption and positive regulatory developments. The bear case (20% probability) sees the stock falling to $142-$170 if regulatory setbacks or slower growth materialize. The analyst consensus average target is ~$244.80, implying 34.3% upside from the current price of $182.27. The most likely scenario is the base case, with total returns of 4-8% annually from dividends and modest price appreciation.
PM appears fairly valued to slightly undervalued based on multiple metrics. The trailing P/E of 22.06x is above the tobacco industry average of ~17x, but this premium is justified by PM's superior growth profile (6.8% revenue growth vs. industry decline) and dominant position in reduced-risk products. The PEG ratio of 0.36 suggests the stock is undervalued relative to its earnings growth rate. Historically, PM's P/E has ranged from 14.3x to 29.2x over the past five years, and the current 22.06x is near the midpoint, indicating the market is pricing in moderate growth expectations. The forward P/E of 19.98x implies a 9.4% discount to trailing, reflecting expected earnings growth.
PM is a good buy for income-oriented investors with a moderate risk tolerance. The stock offers a 3.46% dividend yield supported by strong free cash flow ($10.66B TTM) and a low payout ratio of 76%. With a PEG ratio of 0.36, it appears undervalued relative to its earnings growth, and the analyst consensus is Buy with 34.3% upside to the average target of ~$244.80. However, the stock carries regulatory and leverage risks, and its 1-year return of +3.62% lags the market. It is best suited for long-term holders who can tolerate periodic drawdowns (max -22%) in exchange for steady income and gradual appreciation.
PM is best suited for long-term investment, with a suggested minimum holding period of 3-5 years. The stock's low beta of 0.405 and high dividend yield of 3.46% make it a defensive holding that can provide steady income and capital preservation. Short-term trading is less attractive due to the stock's low volatility and limited upside catalysts in the near term. The company's transition to reduced-risk products is a multi-year story, and long-term investors can benefit from compounding dividends and gradual earnings growth. However, investors should be prepared for periodic drawdowns of up to 22% during regulatory scares or market downturns.